10-Q: NeuroPace Reports Q3 2026 Results, Revenue Up 11%

NeuroPace, Inc. announced its third-quarter 2026 financial results, showing an 11% increase in revenue year-over-year, but continued net losses and cash burn from operations.

Summary

• NeuroPace, Inc. reported third-quarter 2026 results with revenue of $23.1 million, a 1% decrease compared to the prior year's third quarter ($23.4 million).
• For the nine months ended September 30, 2026, revenue increased by 11% to $67.9 million, up from $61.2 million in the same period of 2025.
• The company experienced a net loss of $3.3 million for the three months ended September 30, 2026, compared to a net loss of $3.5 million in the prior year.
• For the nine months ended September 30, 2026, the net loss was $16.2 million, an improvement from $18.7 million in the same period of 2025.
• As of September 30, 2026, the company had $49.2 million in cash, cash equivalents, and short-term investments.
• The company has an accumulated deficit of $568.6 million as of September 30, 2026.
• DIXI Medical product operations have been classified as discontinued operations, with no revenue reported for the three months ended September 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative score due to continued net losses and cash burn, despite revenue growth and improved gross margins. The company's liquidity is sufficient for the next 12 months, but future funding needs and covenant compliance remain key concerns.

Positives

• Revenue for the nine months ended September 30, 2026, increased by 11% to $67.9 million.
• Gross margin improved to 84.3% for the three months ended September 30, 2026, up from 82.1% in the prior year.
• Gross margin for the nine months ended September 30, 2026, increased to 83.0% from 82.6% in the prior year.
• Operating expenses decreased by 7% for the three months ended September 30, 2026, compared to the prior year.
• Loss from continuing operations improved by 32% for the nine months ended September 30, 2026, compared to the prior year.
• The company believes its current cash, cash equivalents, and short-term investments will allow it to continue operations for at least the next 12 months.
• The company was in compliance with all covenants of the MidCap Credit Agreement as of September 30, 2026.

Negatives

• Revenue for the three months ended September 30, 2026, decreased by 1% to $23.1 million compared to $23.4 million in the prior year.
• The company reported a net loss of $3.3 million for the three months ended September 30, 2026.
• The company has an accumulated deficit of $568.6 million as of September 30, 2026.
• Net cash used in operating activities was $12.6 million for the nine months ended September 30, 2026.
• The DIXI Medical distribution agreement expired, and DIXI Medical product operations are now classified as discontinued operations.
• The company may require additional funding to support operations and pay obligations.

Risks

• The company relies on its RNS System as its primary source of revenue, and failure to successfully market and sell it could negatively affect sales and operations.
• Commercial success depends on market acceptance and increasing the number of patients treated; failure to achieve this could harm the business.
• Dependence on a limited number of single-source suppliers makes the company vulnerable to supply shortages and price fluctuations.
• Inability to accurately forecast customer demand could harm results of operations.
• The company is seeking expanded FDA labeling for new patient populations, and failure to obtain these could harm growth potential.
• Failure to comply with U.S. federal and state healthcare laws and regulations could lead to substantial penalties.
• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.
• The MidCap Term Loan contains restrictive covenants, and non-compliance could lead to default and acceleration of debt.

Future Outlook

The company expects to continue to incur net losses and negative cash flows for the near term. Management believes existing cash, cash equivalents, and short-term investments will fund operations for at least the next 12 months. Future funding may be required through equity or debt financings.

Management Comments

• We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment.
• We intend to continue making significant investments in research and development, clinical studies and regulatory affairs to support ongoing and future regulatory submissions for retaining and expanding indications of our RNS System.
• We have invested heavily and expect to continue to invest in research and development and commercial activities.

Industry Context

StockSavvy.ai notes that NeuroPace operates in the highly competitive medical device sector, specifically within neuromodulation for epilepsy. The company faces competition from established players with greater resources and is navigating a complex regulatory environment with the FDA for product approvals and label expansions.

Comparison to Industry Standards

• Competitors like LivaNova plc (VNS System) and Medtronic plc (DBS System) have longer operating histories, greater resources, and established relationships, setting a high bar for market penetration.
• The company's RNS System is the only commercially available brain-responsive neuromodulation system, differentiating it from competitors.
• The FDA's regulatory process for medical devices, including PMA supplements for label expansion, is a standard but rigorous pathway that NeuroPace is navigating.
• The company's focus on real-world evidence studies (e.g., AURORA) aligns with industry trends to support regulatory submissions and market adoption.

Legal Proceedings

• The company is not currently a party to any material legal proceedings that would have a material adverse effect on its business, financial position, results of operations, or cash flows.

Related Party Transactions

• In February 2025, the company used $49.5 million of net proceeds from a follow-on offering to repurchase all shares held by its significant stockholder, KCK Ltd.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Creditors may be impacted by the company's ability to comply with debt covenants.
• Patients with drug-resistant epilepsy may benefit from continued R&D and potential expansion of indications for the RNS System.
• Healthcare providers may face challenges if reimbursement for procedures or ongoing care changes unfavorably.

Next Steps

• Amending PMA-S with supplemental information, including additional data and context regarding patient populations evaluated in the NAUTILUS clinical trial, following discussions with the FDA.
• Continuing to pursue expanded labeling for patients with drug-resistant idiopathic generalized epilepsy and patients aged 12-17 with drug-resistant focal epilepsy.
• Expanding commercial outreach to additional epileptologists and functional neurosurgeons outside of Level 4 Comprehensive Epilepsy Centers.
• Continuing to invest in research and development for product enhancements and new products.
• Monitoring compliance with MidCap Credit Agreement covenants.

Key Dates

Recommendation

NeuroPace shows revenue growth in its core business over nine months, and improved gross margins. However, the company continues to incur significant net losses and cash burn, with a substantial accumulated deficit. The FDA's non-approvable letter for a key indication expansion represents a significant hurdle and potential delay. While liquidity is sufficient for the next 12 months, future funding needs and covenant compliance remain critical. The competitive landscape and regulatory risks are substantial. Therefore, a 'hold' recommendation is appropriate, pending clearer progress on regulatory approvals and a more sustainable path to profitability.

Keywords

RNS System, epilepsy, neuromodulation, medical device, FDA, clinical trials, revenue, net loss